The companies are aiming to use microbial biomarkers to predict the development of precancerous adenomas and carcinomas.
The startup company will use the money to develop its microbial tests and AI-based software for surveillance and prevention of hospital-acquired infections.
After comparing manual methods with the firm's pcr.ai tool in more than 20,000 cases, they found that the use of AI improved test accuracy and reliability.
The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.
The company uses systems biology approaches and AI methods to model and analyze causal pathways in diseases including neurological cancers and Alzheimers.
The trial aims to combine personal information, pharmacogenomics data, and machine-learning tools to select the best anti-seizure medication for patients.
Hitachi and Centre Léon Bérard have opened a research lab in Lyon that will apply AI to medical imaging and predict response to radiation therapy from genomic markers.
InformedDNA's network of remote counselors will augment the AI-driven chatbots offered by OptraHealth's automated GeneFax platform.
Microsoft is applying its Project Hanover AI to Jackson Laboratory's Clinical Knowledgebase to help tumor boards find appropriate therapies based on tumor mutations.
The two companies have been working together since February and now are formalizing plans to develop and test new products.
The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.
The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.